Impact of FGFR2/3 Activating Genomic Alterations on Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma (mUC)

Name: Impact of FGFR2/3 Activating Genomic Alterations on Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma (mUC)
Uploaded: 2021-02-19T00:00:00+00:00
Description: Bladder cancer research: Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC) Senior author: Guru Sonpavde, MD ASCO #GU21 Abstract 472

Bladder cancer research: Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC) Senior author: Guru Sonpavde, MD ASCO #GU21 Abstract 472

Published

February 19, 2021

Created by

Related Presenters

Guru P. Sonpavde, MD

Medical Oncology

Guru P. Sonpavde, MD is the Bladder Cancer Director at Dana Farber Cancer Institute. At Dana-Farber, he leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to cure bladder cancer.

View Profile

Related Videos

Video

Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Kidney Cancer Research: HIF-2a drug combination shows promise in previously treated patients with clear cell renal cell carcinoma. Preliminary results presented by Toni Chouieiri, MD at ASCO #GU21

Video

The Very Favorable Metastatic Renal Cell Carcinoma (mRCC) Risk Group: Data From the International Metastatic RCC Database Consortium (IMDC)

Kidney Cancer Research: Andrew Schmidt, MBBS presents a study that identifies a very favorable risk group in advanced kidney cancer patients treated with first-line therapy. ASCO #GU21 abstract 339.

Video

An Open-Label, Multicenter, Phase IIIb Study of Patients with Urinary Tract Carcinoma (UTC) (STRONG): Final Analysis for Fixed-Dose Durvalumab Monotherapy (Module A)

Bladder Cancer: Guru Sonpavde, MD details STRONG study results presented at ASCO #GU21? that find fixed-dose durvalumab monotherapy safe in patients previously treated for urinary tract carcinoma. Abstract 429

Video

Post-Radical Prostatectomy (RP) Outcome for Patients with High-Risk Prostate Cancer Treated with Intense Neoadjuvant Hormone Therapy (NHT): Results of a Pooled Analysis of Contemporary Clinical Trials

Prostate cancer research: Mary-Ellen Taplin, MD details prostate cancer research findings that indicate decreased PSA relapse rate for patients with a favorable pathologic response to neoadjuvant hormone therapy prior to radical prostatectomy.

Video

Analysis of Plasma KIM-1 as a Biomarker for Recurrence Risk After Resection for Localized Renal Cell Carcinoma

Kidney cancer research: Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma, presented by Vincent Wenxin Xu, MD at ASCO #GU21 abstract 342

Video

Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study

Kidney Cancer Research: Toni Choueiri, MD details results from the phase 3 CLEAR study that showed significant benefits from the combination of lenvatinib, an oral kinase inhibitor, and pembrolizumab, a checkpoint inhibitor in advanced kidney cancer.

Video

Impact of Angiotensin Blockade on Response to PD1/L1 Inhibitors for Patients with Metastatic Urothelial Carcinoma (mUC)

Bladder cancer research presented by Dana-Farber's Guru Sonpavde, MD at ASCO #GU21: Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC) Abstract 453